Dasatinib suppresses collective cell migration through the coordination of focal adhesion and E -cadherin in colon cancer cells
Heliyon, ISSN: 2405-8440, Vol: 10, Issue: 1, Page: e23501
2024
- 3Citations
- 4Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations3
- Citation Indexes3
- CrossRef3
- Captures4
- Readers4
- Mentions1
- News Mentions1
- 1
Most Recent News
New Colon Cancer Study Findings Have Been Reported from Tunghai University (Dasatinib suppresses collective cell migration through the coordination of focal adhesion and E-cadherin in colon cancer cells)
2024 JAN 02 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Investigators publish new report on colon cancer. According to news
Article Description
Collective cell migration is an important process in cancer metastasis. Unlike single-cell migration, collective cell migration requires E -cadherin expression in the cell cohort. However, the mechanisms underlying cellular contact and focal adhesions remain unclear. In this study, Src was hypothesized to coordinate focal adhesion and Rab11-mediated E -cadherin distribution during collective cell migration. This study primarily used confocal microscopy to visualize the 3D structure of cell-cell contacts with associated molecules. These results demonstrate that the clinical Src inhibitor dasatinib was less toxic to HT-29 colon cancer cells; instead, the cells aggregated. 3D immunofluorescence imaging showed that Rab11 was localized with E -cadherin at the adherens junctions of the apical cell-cell contacts. In the transwell assay, Rab11 colocalized with a broad range of E -cadherin proteins in collectively migrated cells, and dasatinib treatment significantly suppressed collective cell migration. Transmission electron microscopy demonstrated that dasatinib treatment increased cell membrane protrusion contacts and generated spaces between cells, which may allow epidermal growth factor receptor activity at the cell-cell contacts. This study suggests that dasatinib treatment does not inhibit cell survival but targets Src at different cellular compartments in the coordination of focal adhesions and cell-cell contacts in collective cell migration through E -cadherin dynamics in colon cancer cells.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2405844023107092; http://dx.doi.org/10.1016/j.heliyon.2023.e23501; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85180811380&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/38187289; https://linkinghub.elsevier.com/retrieve/pii/S2405844023107092; https://dx.doi.org/10.1016/j.heliyon.2023.e23501
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know